What is the iodine content percentage in amiodarone?
Which of the following medications is known to cause increased renin levels with prolonged use?
Which of the following is NOT caused by Prostaglandin E2 (PGE2)?
What is the antidote for Ethylene Glycol?
Which of the following is the mechanism of action of tetanospasmin ?
What is the primary cardiotoxic effect of bupivacaine?
What is the best drug for open-angle glaucoma?
Which of the following best describes a Type B adverse drug reaction?
Which of the following statements about dopamine is false?
Which of the following is a centrally acting antihypertensive drug?
NEET-PG 2012 - Pharmacology NEET-PG Practice Questions and MCQs
Question 21: What is the iodine content percentage in amiodarone?
- A. 10 - 20%
- B. 20 - 40% (Correct Answer)
- C. 40 - 60%
- D. 60 - 80%
Explanation: ***20 - 40%*** - **Amiodarone** is highly lipophilic and contains a significant amount of **iodine**, typically comprising around **37.5%** of its molecular weight. - This high iodine content is responsible for many of its **adverse effects**, particularly those related to thyroid dysfunction. *10 - 20%* - This range is too low; the actual iodine content in **amiodarone** is considerably higher, making it a prominent feature of the drug's chemical structure. - A lower iodine percentage would likely result in fewer **thyroid-related side effects**. *40 - 60%* - While amiodarone has a high iodine content, 40-60% is slightly above the generally accepted range. - Iodine constitutes a substantial but not an overwhelming majority of the drug's molecular mass. *60 - 80%* - This range is significantly higher than the actual iodine content in **amiodarone**. - Such a high percentage would imply an even greater propensity for **iodine-induced adverse effects**.
Question 22: Which of the following medications is known to cause increased renin levels with prolonged use?
- A. Clonidine
- B. Enalapril (Correct Answer)
- C. Methyldopa
- D. Propranolol
Explanation: ***Enalapril*** - **Enalapril** is an **ACE inhibitor** which blocks the conversion of angiotensin I to angiotensin II, leading to decreased levels of angiotensin II [1]. - Reduced angiotensin II levels remove the **negative feedback** on renin release from the juxtaglomerular cells, thus increasing renin secretion [1], [2]. *Clonidine* - Clonidine is a **central alpha-2 adrenergic agonist** that reduces sympathetic outflow from the central nervous system. - This reduction in sympathetic activity leads to a **decrease in renin release**, as sympathetic stimulation normally promotes renin secretion [3]. *Methyldopa* - Methyldopa is a **central alpha-2 adrenergic agonist** that works similarly to clonidine by reducing sympathetic tone. - It consequently causes a **decrease in plasma renin activity** due to reduced sympathetic stimulation of the juxtaglomerular apparatus [3]. *Propranolol* - Propranolol is a **non-selective beta-blocker** that blocks beta-1 receptors in the juxtaglomerular cells of the kidney. - This blockade **inhibits the release of renin** stimulated by sympathetic activity, leading to reduced renin levels [3].
Question 23: Which of the following is NOT caused by Prostaglandin E2 (PGE2)?
- A. None of the options (Correct Answer)
- B. Water retention
- C. Flushing
- D. Uterine contraction
Explanation: ***None of the options*** - All three listed effects (water retention, uterine contraction, and flushing) **ARE caused by Prostaglandin E2 (PGE2)**, making this the correct answer to the question asking what is NOT caused by PGE2. - Since PGE2 actually causes all the listed effects, "None of the options" is the accurate response. *Water retention* - PGE2 **stimulates ADH (vasopressin) release** from the posterior pituitary gland. - PGE2 also **enhances ADH action** on renal collecting ducts, promoting water reabsorption. - While PGE2 has complex renal effects including natriuresis, its net effect includes **promoting water retention** through the ADH mechanism. - This is an important effect of PGE2 on fluid balance. *Uterine contraction* - PGE2 is a **potent stimulator of uterine smooth muscle contraction**. - It is used clinically for **labor induction** and **cervical ripening** (dinoprostone). - PGE2 plays a crucial role in **parturition** and is involved in **dysmenorrhea**. *Flushing* - PGE2 causes **peripheral vasodilation**, particularly in cutaneous blood vessels. - This vasodilatory effect leads to **increased skin blood flow**, manifesting as **flushing** and warmth. - This is commonly seen as part of the **inflammatory response** and contributes to erythema.
Question 24: What is the antidote for Ethylene Glycol?
- A. Barbiturate
- B. Acetylcysteine
- C. Ferric chloride
- D. Fomepizole (Correct Answer)
Explanation: ***Fomepizole*** - **Fomepizole** is the primary and preferred antidote for ethylene glycol poisoning, as it competitively inhibits **alcohol dehydrogenase**, the enzyme responsible for metabolizing ethylene glycol into its toxic metabolites. - By blocking this enzyme, fomepizole prevents the formation of harmful compounds like **glycolic acid** and **oxalic acid**, which cause metabolic acidosis and kidney damage. - **Ethanol** is an alternative antidote that works by the same mechanism (competitive inhibition of alcohol dehydrogenase) and can be used when fomepizole is unavailable, though fomepizole is preferred due to better safety profile and easier dosing. *Barbiturate* - **Barbiturates** are a class of psychoactive drugs that act as central nervous system depressants, primarily used for sedation, anesthesia, and seizure control. - They have no role in neutralizing or metabolizing ethylene glycol or its toxic byproducts. *Acetylcysteine* - Acetylcysteine is an antidote primarily used for **acetaminophen (paracetamol) overdose**, where it replenishes glutathione stores and detoxifies its toxic metabolite, **NAPQI**. - It does not have any direct antidotal effect against ethylene glycol or its metabolites. *Ferric chloride* - **Ferric chloride** is a chemical compound used in various industrial processes, water treatment, and as a laboratory reagent. - It is highly corrosive and toxic if ingested, but it is not used as an antidote for any type of poisoning, including ethylene glycol.
Question 25: Which of the following is the mechanism of action of tetanospasmin ?
- A. Inhibition of release of GABA and glycine (Correct Answer)
- B. Inhibition of Ach release from synapse
- C. Inhibition of protein synthesis
- D. Activation of adenylyl cyclase
Explanation: ***Inhibition of release of GABA and glycine*** - **Tetanospasmin** is a potent neurotoxin produced by *Clostridium tetani* that acts by blocking the release of inhibitory neurotransmitters, specifically **GABA (gamma-aminobutyric acid)** and **glycine**, from presynaptic terminals in the spinal cord and brainstem. - This inhibition leads to **uncontrolled muscle spasms**, rigidity, and convulsions, characteristic of tetanus, due to the lack of inhibitory signals to motor neurons. *Inhibition of Ach release from synapse* - This mechanism is characteristic of **botulinum toxin** (produced by *Clostridium botulinum*), not tetanospasmin. - Botulinum toxin inhibits the release of **acetylcholine (ACh)** at the neuromuscular junction, leading to flaccid paralysis. *Inhibition of protein synthesis* - This mechanism is associated with toxins like **diphtheria toxin** and **exotoxin A** from *Pseudomonas aeruginosa*. - These toxins inactivate elongation factor-2 (EF-2), thereby blocking protein synthesis and causing cell death. *Activation of adenylyl cyclase* - Toxins such as **cholera toxin** and **pertussis toxin** act by activating adenylyl cyclase, leading to an increase in intracellular cAMP levels. - This mechanism causes effects like severe diarrhea in cholera and respiratory symptoms in whooping cough.
Question 26: What is the primary cardiotoxic effect of bupivacaine?
- A. Depressed pacemaker activity (Correct Answer)
- B. Toxic compound damaging myocardial cells
- C. Depressed neural control on heart
- D. Vascular thrombosis and Myocardial ischemia
Explanation: ***Depressed pacemaker activity*** - **Bupivacaine** is a potent **local anesthetic** that blocks voltage-gated **sodium channels** in myocardial cells with **high affinity** and **slow dissociation kinetics**. - This prolonged channel blockade leads to decreased cardiac excitability and **depressed automaticity** of pacemaker cells, particularly affecting the **SA node** and **His-Purkinje system**. - Results in slowing of the **heart rate**, **bradyarrhythmias**, **conduction blocks**, and potentially **ventricular arrhythmias** or **asystole**. - Bupivacaine is **more cardiotoxic** than other local anesthetics due to its **lipophilicity** and prolonged binding to cardiac sodium channels. *Toxic compound damaging myocardial cells* - While **bupivacaine** is cardiotoxic, its primary mechanism is not direct **cellular damage** through cytotoxic effects, oxidative stress, or cell membrane lysis. - The toxicity is predominantly due to **electrophysiological effects** on ion channels, interfering with normal cardiac conduction and contractility. *Depressed neural control on heart* - **Bupivacaine's** cardiotoxicity primarily affects the **myocardium directly** through sodium channel blockade, rather than indirectly through the **autonomic nervous system**. - Although high systemic concentrations can affect the **central nervous system** (causing seizures and CNS depression), the direct cardiac effects occur independently of neural influence. *Vascular thrombosis and Myocardial ischemia* - **Bupivacaine** cardiotoxicity does not typically involve formation of **thrombi** or mechanisms leading to **myocardial ischemia** through coronary artery occlusion. - Its effects are predominantly on the **electrical conduction system**, **myocardial contractility**, and **cardiac ion channels**, not the vascular supply to the heart.
Question 27: What is the best drug for open-angle glaucoma?
- A. Latanoprost (Correct Answer)
- B. Pilocarpine
- C. Physostigmine
- D. Apraclonidine
Explanation: Latanoprost - Latanoprost is a prostaglandin analog and is often considered a first-line treatment for open-angle glaucoma due to its efficacy in reducing intraocular pressure (IOP) and its once-daily dosing. - It works by increasing the outflow of aqueous humor through the uveoscleral pathway, thereby lowering IOP. Pilocarpine - Pilocarpine is a cholinergic agonist that causes miosis and ciliary muscle contraction [3], increasing the outflow of aqueous humor through the trabecular meshwork [4]. - While effective, its side effects (e.g., accommodative spasm, miosis) [1] and more frequent dosing make it generally a second-line or third-line agent for long-term management compared to prostaglandins. Physostigmine - Physostigmine is an acetylcholinesterase inhibitor that indirectly increases acetylcholine, mimicking cholinergic stimulation. - Although it can lower IOP, it is generally not used for open-angle glaucoma due to significant side effects and the availability of safer, more effective alternatives [1]. Apraclonidine - Apraclonidine is an alpha-2 adrenergic agonist [2] used primarily for short-term control of IOP, especially before or after ocular surgery, or as an adjunct therapy. - Its efficacy as a long-term monotherapy for open-angle glaucoma is limited by tachyphylaxis and potential for significant systemic side effects with chronic use.
Question 28: Which of the following best describes a Type B adverse drug reaction?
- A. Augmented effect of drug
- B. Effect seen on chronic use of drug
- C. Delayed effect of drug
- D. Unpredictable bizarre reaction (Correct Answer)
Explanation: ***Unpredictable bizarre reaction*** - Type B reactions are **unpredictable**, **bizarre**, and not directly related to the drug's known pharmacological actions. - They often involve **immunological reactions** or genetic predispositions, such as allergies or idiosyncratic responses. *Augmented effect of drug* - This describes a **Type A** adverse drug reaction, which is predictable and results from an **exaggerated pharmacological effect** of the drug. - It is typically dose-dependent and can be managed by adjusting the dosage. *Effect seen on chronic use of drug* - This description can apply to several types of adverse reactions, but it commonly relates to **Type C (chronic) reactions**, where effects occur only after prolonged exposure. - These reactions might be due to **cumulative toxicity** or adaptive changes in the body. *Delayed effect of drug* - This aligns with **Type D (delayed) adverse drug reactions**, which manifest long after the drug exposure has ended or after a period of latency. - Examples include **carcinogenesis** or teratogenesis, occurring months or years later.
Question 29: Which of the following statements about dopamine is false?
- A. Improves renal perfusion
- B. Causes Vasoconstriction
- C. Causes increase in GI Ischemia (Correct Answer)
- D. Positive ionotropic
Explanation: ***Causes increase in GI Ischemia*** (FALSE Statement) - This statement is **incorrect and misleading** as dopamine does not primarily "cause increase in GI ischemia" - While dopamine at **higher doses** can cause **splanchnic vasoconstriction** via alpha-1 receptors, this is not characterized as "causing GI ischemia" in standard pharmacology - GI ischemia is a potential adverse effect in susceptible patients, but not a primary pharmacological effect or standard clinical description of dopamine *Positive inotropic* (TRUE Statement) - Dopamine is a **catecholamine** with dose-dependent effects; at **moderate doses (5-10 mcg/kg/min)**, it stimulates **beta-1 adrenergic receptors** in the heart - This beta-1 stimulation leads to increased **myocardial contractility** and **heart rate**, thus exerting a **positive inotropic effect** - This is a well-established therapeutic effect of dopamine *Improves renal perfusion* (TRUE Statement) - At **low doses (0.5-3 mcg/kg/min)**, dopamine selectively activates **dopamine-1 (D1) receptors** in the renal vasculature - This activation causes **renal vasodilation**, leading to increased **renal blood flow**, improved **glomerular filtration rate**, and enhanced **sodium excretion** - This "renal dose" effect is a classic pharmacological property of dopamine *Causes Vasoconstriction* (TRUE Statement) - At **high doses (>10 mcg/kg/min)**, dopamine primarily stimulates **alpha-1 adrenergic receptors** - This leads to generalized **vasoconstriction**, increasing **systemic vascular resistance** and **blood pressure** - This dose-dependent alpha effect is well-documented
Question 30: Which of the following is a centrally acting antihypertensive drug?
- A. Phenoxybenzamine
- B. Propranolol
- C. Prazosin
- D. Methyldopa (Correct Answer)
Explanation: ***Methyldopa*** - **Methyldopa** is a **prodrug** that is converted to **alpha-methylnorepinephrine** in the brain, which then stimulates **alpha-2 adrenergic receptors** in the brainstem. - This stimulation reduces **sympathetic outflow** from the central nervous system, leading to decreased heart rate, stroke volume, and peripheral vascular resistance, thus lowering blood pressure. *Phenoxybenzamine* - **Phenoxybenzamine** is an **alpha-1 and alpha-2 adrenergic receptor antagonist** (non-selective alpha blocker) that primarily acts peripherally. - It causes **vasodilation** by blocking alpha-1 receptors on smooth muscle, which reduces peripheral vascular resistance. *Propranolol* - **Propranolol** is a **non-selective beta-blocker** that primarily acts on peripheral beta-adrenergic receptors. - It reduces heart rate and cardiac output by blocking **beta-1 receptors** in the heart and can also affect beta-2 receptors in the lungs and vasculature. *Prazosin* - **Prazosin** is a **selective alpha-1 adrenergic receptor antagonist** that acts primarily on peripheral blood vessels. - It causes **vasodilation** in both arteries and veins by blocking alpha-1 receptors, which reduces both preload and afterload, lowering blood pressure.